52 related articles for article (PubMed ID: 26744522)
21. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.
Sorace AG; Quarles CC; Whisenant JG; Hanker AB; McIntyre JO; Sanchez VM; Yankeelov TE
Breast Cancer Res Treat; 2016 Jan; 155(2):273-84. PubMed ID: 26791520
[TBL] [Abstract][Full Text] [Related]
22. Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Can We Understand It Better?
Loi S; Savas P
J Clin Oncol; 2016 Feb; 34(6):521-3. PubMed ID: 26755511
[No Abstract] [Full Text] [Related]
23. A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.
Zhong H; Davis A; Ouzounova M; Carrasco RA; Chen C; Breen S; Chang YS; Huang J; Liu Z; Yao Y; Hurt E; Moisan J; Fung M; Tice DA; Clouthier SG; Xiao Z; Wicha MS; Korkaya H; Hollingsworth RE
Cancer Res; 2016 Jan; 76(2):480-90. PubMed ID: 26744529
[TBL] [Abstract][Full Text] [Related]
24. A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.
Li M; Xing S; Zhang H; Shang S; Li X; Ren B; Li G; Chang X; Li Y; Li W
Oncol Rep; 2016 Mar; 35(3):1329-39. PubMed ID: 26752000
[TBL] [Abstract][Full Text] [Related]
25. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
Luhtala S; Staff S; Tanner M; Isola J
Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
[TBL] [Abstract][Full Text] [Related]
26. Interleukine-2 serum level in breast cancer patients.
Harjianti T; Fachruddin A; Minhajat R; Saleh S; Bayu D
Caspian J Intern Med; 2023; 14(3):479-484. PubMed ID: 37520880
[TBL] [Abstract][Full Text] [Related]
27. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
Yu K; Basu A; Yau C; Wolf DM; Goodarzi H; Bandyopadhyay S; Korkola JE; Hirst GL; Asare S; DeMichele A; Hylton N; Yee D; Esserman L; van 't Veer L; Sirota M
Front Oncol; 2023; 13():1192208. PubMed ID: 37384294
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive evaluation of breast cancer immunotherapy and tumor microenvironment characterization based on interleukin genes-related risk model.
Lv Y; Bai Z; Wang X; Liu J; Li Y; Zhang X; Shan Y
Sci Rep; 2022 Nov; 12(1):20524. PubMed ID: 36443508
[TBL] [Abstract][Full Text] [Related]
29. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.
Petroni G; Buqué A; Coussens LM; Galluzzi L
Nat Rev Drug Discov; 2022 Jun; 21(6):440-462. PubMed ID: 35292771
[TBL] [Abstract][Full Text] [Related]
30. Targeting
Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
Front Immunol; 2021; 12():738958. PubMed ID: 34721405
[TBL] [Abstract][Full Text] [Related]
31. Beyond immune checkpoint blockade: emerging immunological strategies.
Kubli SP; Berger T; Araujo DV; Siu LL; Mak TW
Nat Rev Drug Discov; 2021 Dec; 20(12):899-919. PubMed ID: 33686237
[TBL] [Abstract][Full Text] [Related]
32. A novel immune prognostic index for stratification of high-risk patients with early breast cancer.
Lee H; Kwon MJ; Koo BM; Park HG; Han J; Shin YK
Sci Rep; 2021 Jan; 11(1):128. PubMed ID: 33420250
[TBL] [Abstract][Full Text] [Related]
33. Molecular Profiling of Exceptional Responders to Cancer Therapy.
Bilusic M; Girardi D; Zhou Y; Jung K; Pei J; Slifker M; Chen Q; Meerzaman D; Alpaugh K; Young D; Flieder D; Gray P; Plimack E
Oncologist; 2021 Mar; 26(3):186-195. PubMed ID: 33210795
[TBL] [Abstract][Full Text] [Related]
34. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells.
Deng S; Sun Z; Qiao J; Liang Y; Liu L; Dong C; Shen A; Wang Y; Tang H; Fu YX; Peng H
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271164
[TBL] [Abstract][Full Text] [Related]
35. Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy.
Mittal D; Vijayan D; Neijssen J; Kreijtz J; Habraken MMJM; Van Eenennaam H; Van Elsas A; Smyth MJ
Oncoimmunology; 2019; 8(11):e1648171. PubMed ID: 31646095
[TBL] [Abstract][Full Text] [Related]
36. Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs.
Jiang N; Lin JJ; Wang J; Zhang BN; Li A; Chen ZY; Guo S; Li BB; Duan YZ; Yan RY; Yan HF; Fu XY; Zhou JL; Yang HM; Cui Y
Exp Ther Med; 2018 Sep; 16(3):2183-2192. PubMed ID: 30186457
[TBL] [Abstract][Full Text] [Related]
37. Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.
Di Modica M; Tagliabue E; Triulzi T
Dis Markers; 2017; 2017():7849108. PubMed ID: 29403144
[TBL] [Abstract][Full Text] [Related]
38. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.
Muntasell A; Cabo M; Servitja S; Tusquets I; Martínez-García M; Rovira A; Rojo F; Albanell J; López-Botet M
Front Immunol; 2017; 8():1544. PubMed ID: 29181007
[TBL] [Abstract][Full Text] [Related]
39. Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?
Deligne C; Milcent B; Josseaume N; Teillaud JL; Sibéril S
Front Immunol; 2017; 8():950. PubMed ID: 28855903
[TBL] [Abstract][Full Text] [Related]
40. Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.
Mittal D; Caramia F; Michiels S; Joensuu H; Kellokumpu-Lehtinen PL; Sotiriou C; Loi S; Smyth MJ
Cancer Res; 2016 Jan; 76(2):264-74. PubMed ID: 26744522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
